Synlait said it is seeing no "material short-term impact" from Covid-19, although the outbreak "represents some downside risk going forward."
Profit was supported by the sales of consumer-packaged infant formula, which lifted 22 per cent on the same period. Total revenue was up 19 per cent at $559m and milk processed rose 8.5 per cent to 46.7 million kgMS.
Net profit was weighed on by higher depreciation and interest costs as Synlait invests for growth, it said.
Among other things it had a $3.2m increase in employee costs "reflecting ongoing investment in people," it said.
Net debt, meanwhile, rose from $159.7m to $447.4m in the half year with $220m of capital expenditure.
Funds were used for a second infant-capable manufacturing facility in Pokeno and an advanced dairy liquid packaging plant at Dunsandel.
Regarding legal issues surrounding its Pokeno factory, it said "uncertainty remains regarding land at Synlait Pokeno." However, the company remains comfortable with its legal position ahead of the Supreme Court hearing scheduled for April.
Last year, Synlait won the right to appeal a decision restricting the land where its new $260m Pokeno factory has been built to grazing, lifestyle farming and forestry.
The shares closed at $4.62 yesterday, having slumped 48 per cent so far this year.